Selective Neck Dissection Versus Modified Neck Dissection in PTC

Launched by FUDAN UNIVERSITY · Aug 14, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two different surgical techniques for patients with a type of thyroid cancer called papillary thyroid carcinoma (PTC). The goal is to see if a procedure called selective neck dissection, which removes fewer lymph nodes, is as safe and effective as a modified neck dissection, which removes more lymph nodes. Researchers want to understand not only how well these surgeries work but also how they affect patients' quality of life after the procedure.

To participate in the trial, individuals must be between 14 and 80 years old and have been diagnosed with PTC that has spread to a limited number of lymph nodes in the neck. Patients should have specific features in their medical imaging that indicate the cancer is contained and not aggressive. People with previous neck surgeries or other serious health issues may not be eligible. Participants will be randomly assigned to one of the two surgical groups and will be monitored for their recovery and overall well-being. It's important to know that this trial is not yet recruiting participants, so there will be a waiting period before it starts.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pathologically confirmed PTC;
• • Age range: 14-80 years old;
• • Preoperative fine needle aspiration confirms lymph node metastasis in the lateral neck
• • Ultrasound and CT suggest that metastatic/suspected metastatic lymph nodes are limited to compartment IV, with 1-2 lymph node metastases and \<1cm in short diameter. The lymph nodes have no central necrosis, liquefaction, peripheral enhancement, or disappearance of adjacent fat spaces (predicting unobstructed lymphatic vessels);
• • Thyroid tumors without extra thyroidal extension;
• • Enough thyroid volume to inject tracer.
• Exclusion Criteria:
• • Previous neck surgery;
• • Bilateral neck lymph node dissection;
• • Distant metastases;
• • High risk pathological subtypes or the presence of other high-risk factors for recurrence;
• • Previous treatment for thyroid cancer other than endocrine therapy;
• • The patient is unable to cooperate with follow-up.